Search Results - "Debled M"

Prise en charge du cancer du sein infiltrant de la femme âgée de 40 ans ou moins.

Authors: Chauvet, M. Debled, M. Decanter, C. et al.

Source: Oncologie (Tech Science Press). Oct2011, Vol. 13 Issue 10/11, p703-726. 24p.

Les grands challenges de la prise en charge en phase métastatique aujourd’hui.

Alternate Title: Major challenges in the current management of metastatic cancer.

Authors: Guiu, S. Debled, M.

Source: Oncologie (Tech Science Press). Apr2010, Vol. 12 Issue 4, p278-284. 7p.

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.

Authors: Debled, M. Houédé, N. Madranges, N. et al.

Source: British Journal of Cancer. 12/17/2007, Vol. 97 Issue 12, p1642-1647. 6p. 1 Diagram, 3 Charts.

Chimiothérapie adjuvante du cancer du sein du sujet âgé.

Alternate Title: Adjuvant chemotherapy for elderly breast cancer patients.

Authors: Girre, V. Debled, M. Giely, D. et al.

Source: Oncologie (Tech Science Press). jan2006, Vol. 8 Issue 1, p3-9. 7p.

Neoadjuvant chemotherapy: are we barking up the right tree?

Authors: Debled, M. Mauriac, L.

Source: Annals of Oncology. Apr2010, Vol. 21 Issue 4, p675-679. 5p. 1 Chart.

Chimiothérapie et qualité de vie dans le cancer du sein métastatique: état des lieux.

Alternate Title: Chemotherapy and quality of life in metastatic breast cancer: taking stock.

Authors: Serin, D. Brédart, A. Debled, M. et al.

Source: Oncologie (Tech Science Press). Oct2008, Vol. 10 Issue 10, p580-590. 11p. 2 Charts.

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas.

Authors: Soubeyran, P Hostein, I Debled, M et al.

Source: British Journal of Cancer. 11/1/99, Vol. 81 Issue 5, p860. 10p.

372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database.

Authors: Pflumio, C. Carton, M. Debled, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS374-S375. 2p.

Doxorubin-based adjuvant chemotherapy for elderly patients with hormone receptors negative breast carcinoma: a French geriatric oncology group (GERICO) phase II multicentric program

Authors: Debled, M. Girre, V. Mertens, C. et al.

Source: Critical Reviews in Oncology/Hematology. Oct2008 Supplement 2, Vol. 68, pS24-S25. 0p.

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer

Authors: Bonnefoi, H. Zaman, K. Debled, M. et al.

Source: European Journal of Cancer. Jan2013, Vol. 49 Issue 2, p281-289. 9p.

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.

Authors: Frenel, J.-S. Lusque, A. Delaloge, S. et al.

Source: British Journal of Cancer. Jun2023, Vol. 128 Issue 11, p2072-2080. 9p.

279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016.

Authors: Delaloge, S. Antoine, A. Debled, M. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS352-S353. 2p.

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.

Authors: Gaillard, T. Carton, M. Mailliez, A. et al.

Source: European Journal of Cancer. Nov2021, Vol. 158, p181-188. 8p.

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.

Authors: Ravaud, A. Trufflandier, N. Ferrière, J.M. et al.

Source: British Journal of Cancer. 12/15/2003, Vol. 89 Issue 12, p2213-2218. 6p.

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.

Authors: Ravaud, A Delaunay, M Chevreau, C et al.

Source: British Journal of Cancer. 11/15/2001, Vol. 85 Issue 10, p1467. 5p.

238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort.

Authors: Cherifi, F. Cabel, L. Bousrih, C. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS312-S313. 2p.

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

Authors: Ploquin, A. Pistilli, B. Tresch, E. et al.

Source: European Journal of Cancer. May2018, Vol. 95, p30-37. 8p.

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients.

Authors: Jacquet, E. Lardy-Cléaud, A. Pistilli, B. et al.

Source: European Journal of Cancer. May2018, Vol. 95, p93-101. 9p.

Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.

Authors: Dezellus, A. Barriere, P. Campone, M. et al.

Source: European Journal of Cancer. Jul2017, Vol. 79, p72-80. 9p.

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Authors: Delaloge, S. Pérol, D. Courtinard, C. et al.

Source: Annals of Oncology. Sep2016, Vol. 27 Issue 9, p1725-1732. 8p. 1 Diagram, 2 Charts, 2 Graphs.